Method for treating disseminated cancer
AssigneeSentoClone International AB
InventorsOla Winqvist, Magnus Thörn
Life of this patent
Estimating the term…
Abstract
The present invention discloses an immunotherapeutic method for treating a patient suffering from a disseminated cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more metastasis-draining lymph nodes (metinel nodes) draining a metastasis. The method comprises identification of one or more metinel lymph nodes in a patient, resection of the one or more nodes and, optionally all or part of the metastases, isolation of metastasis-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said metastasis-reactive T-lymphocytes, and administration of the thus obtained T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes.
Claims24
A method for treating a patient suffering from a disseminated cancer, the method comprising:
- i) identifying in a patient one or more metinel lymph nodes, and, optionally, identifying all or part of metastases of the disseminated cancer;
- ii) resecting the one or more nodes and, optionally, all or part of the metastases;
- iii) isolating metastasis-reactive T-lymphocytes from said lymph nodes;
- iv) in vitro expanding said metastasis-reactive T-lymphocytes;
- and
- v) administering the thus obtained T-lymphocytes to the patient,
- wherein the T-lymphocytes are CD4+helper or CD8+T-lymphocytes.
A method for treating a patient suffering from a disseminated cancer, the method comprising administering T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+helper or CD8+T-lymphocytes and are obtained by:
- i) identifying in a patient one or more metinel lymph nodes, and, optionally, identifying all or part of metastases of the disseminated cancer;
- ii) resecting the one or more nodes and, optionally, all or part of the metastases;
- iii) isolating metastasis-reactive T-lymphocytes from said lymph nodes;
- and
- iv) in vitro expanding said metastasis-reactive T-lymphocytes by a method comprising:
- (a) a first phase of stimulating tumour-reactive CD4+helper or CD8+T-lymphocytes with tumour-derived antigen together with at least one substance having agonistic activity towards the IL-2 receptor to promote survival of tumour-reactive CD4+helper or CD8+T-lymphocytes;
- and
- (b) a second phase of activating and promoting growth of tumour-reactive CD4+helper or CD8+T-lymphocytes, wherein the second phase is initiated when the CD25 cell surface marker or IL-2R marker is down-regulated on T-lymphocytes.
Dependencies are inferred from the claim text.